CO5011115A1 - Compuestos y metodos quimioquina - Google Patents

Compuestos y metodos quimioquina

Info

Publication number
CO5011115A1
CO5011115A1 CO98058321A CO98058321A CO5011115A1 CO 5011115 A1 CO5011115 A1 CO 5011115A1 CO 98058321 A CO98058321 A CO 98058321A CO 98058321 A CO98058321 A CO 98058321A CO 5011115 A1 CO5011115 A1 CO 5011115A1
Authority
CO
Colombia
Prior art keywords
alkyl
hydrogen
benzyloxy
alkylthio
halo
Prior art date
Application number
CO98058321A
Other languages
English (en)
Inventor
William E Bondinell
James Chan
Roderick A Porter
Joseph W Venslavsky
Original Assignee
Smithkline Beecham Corp
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Smithkline Beecham Plc filed Critical Smithkline Beecham Corp
Publication of CO5011115A1 publication Critical patent/CO5011115A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

El uso del compuesto de la Fórmula (I) para tratar un estadode enfermedad mediado por CCR5 en mamíferos, que comprende administrar a un mamífero que necesita dicho tratamiento una cantidad eficaz de un compuesto de fórmula (I) o una sal farmacéuticamente aceptable del mismo: en la que: X es hidrógeno o uno o más de alquilo C1 -C6 , CONRR´, trifluorometilo, hidroxi, alcoxi C1 -C6 , benciloxi, alquiltio C1 -C6 , o halo, en donde R y R´ son independientemente hidrógeno o alquilo C1 -C6 ; R1 es hidrógeno o alquilo C1 -C6 ; R2 es hidrógeno o alquilo C1 -C6 ; la línea discontinua, ---, indica un enlace sencillo o un enlace doble; R3 es hidrógeno o alquilo C1 -C6 ; A es [C(R")2 ]m CR"R4 R5 ó [C(R")2 ]n CR"-CR4 R5 en donde R", en cada caso, es independiendientemente hidrógeno o alquilo C1 -C6 ; m es de 0 a 3; n es 1 ó 2; R4 es fenilo, bifenilo, naftilo, 1-benzotriazinilo o 2-benzotriazinilo, opcionalmente sustituido con uno o más de alquilo C1 -C6 , ciano, trifluorometilo, NR6 R7 , nitro, hidroxi, alcoxi C1 -C6 , benciloxi, alquiltio C1 -C6 , o halo, donde R6 y R7 son independientemente hidrógeno o alquilo C1 -C6 ; R5 es R" cuando m es 0; alternativamente, R5 es R", fenilo o naftilo cuando m es de 1 a 3 o n es de 1 a 2, en donde fenilo o naftilo están opcionalmente sustituidos con uno o más de alquilo C1 -C6 , ciano, trifluorometilo, NR6 R7 , nitro, hidroxi, alcoxi C1 -C6 , benciloxi, alquiltio C1 -C6 o halo.
CO98058321A 1997-10-07 1998-10-07 Compuestos y metodos quimioquina CO5011115A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6121797P 1997-10-07 1997-10-07

Publications (1)

Publication Number Publication Date
CO5011115A1 true CO5011115A1 (es) 2001-02-28

Family

ID=22034401

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98058321A CO5011115A1 (es) 1997-10-07 1998-10-07 Compuestos y metodos quimioquina

Country Status (9)

Country Link
US (1) US6476028B1 (es)
EP (1) EP1037635A4 (es)
JP (1) JP2001518505A (es)
AR (1) AR013669A1 (es)
AU (1) AU9790198A (es)
CA (1) CA2305805A1 (es)
CO (1) CO5011115A1 (es)
WO (1) WO1999017773A1 (es)
ZA (1) ZA989083B (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025154A (en) 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
US6743594B1 (en) 1995-06-06 2004-06-01 Human Genome Sciences, Inc. Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5)
US7217714B1 (en) * 1998-12-23 2007-05-15 Agouron Pharmaceuticals, Inc. CCR5 modulators
EP1013276A1 (en) 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkanes as CCR5 modulators
PE20001420A1 (es) * 1998-12-23 2000-12-18 Pfizer Moduladores de ccr5
US6635646B1 (en) 1999-05-04 2003-10-21 Schering Corporation Pegylated interferon alfa-CCR5 antagonist combination HIV therapy
HUP0202734A3 (en) * 1999-05-04 2003-11-28 Schering Corp Use of pegylated interfron alfa-ccr5 antagonist combination for hiv therapy
ES2165274B1 (es) * 1999-06-04 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de indolilpiperidina como agentes antihistaminicos y antialergicos.
SE9903544D0 (sv) 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
AR025884A1 (es) 1999-10-01 2002-12-18 Takeda Pharmaceutical Compuestos de amina ciclica, su produccion y su uso
GB2359081A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
GB2359078A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB0005642D0 (en) * 2000-03-10 2000-05-03 Astrazeneca Uk Ltd Chemical compounds
US6667314B2 (en) 2000-05-26 2003-12-23 Pfizer, Inc. Tropane derivatives useful in therapy
DE60102233T2 (de) * 2000-05-26 2005-01-27 Pfizer Inc. Triazolyltropanderivate als ccr5-modulatoren
AU2001280599A1 (en) * 2000-07-15 2002-01-30 Smith Kline Beecham Corporation Compounds and methods
SE0003828D0 (sv) 2000-10-20 2000-10-20 Astrazeneca Ab Novel compounds
ES2172436B1 (es) 2000-10-31 2004-01-16 Almirall Prodesfarma Sa Derivados de indolilpiperidina como agentes antihistaminicos y antialergicos.
SE0101322D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
SE0103818D0 (sv) 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
AR039385A1 (es) 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
CN1787996B (zh) * 2003-03-14 2010-06-16 小野药品工业株式会社 含氮杂环衍生物以及包含所述化合物作为活性成分的药物
WO2004080966A1 (ja) 2003-03-14 2004-09-23 Ono Pharmaceutical Co., Ltd. 含窒素複素環誘導体およびそれらを有効成分とする薬剤
EP1619193A4 (en) 2003-04-18 2010-08-11 Ono Pharmaceutical Co SPIROPIPERIDINE COMPOUND AND MEDICINAL USE THEREOF
SE0301369D0 (sv) * 2003-05-09 2003-05-09 Astrazeneca Ab Chemical compounds
RU2382037C2 (ru) 2003-11-17 2010-02-20 Бёрингер Ингельхайм Интернациональ Гмбх Новые пиперидинзамещенные индолы или их гетеропроизводные
GB0328243D0 (en) 2003-12-05 2004-01-07 Astrazeneca Ab Methods
US20050245540A1 (en) * 2003-12-09 2005-11-03 Fujisawa Pharmaceutical Co., Ltd. New methods
CA2548502A1 (en) 2003-12-11 2005-06-30 Yale University Methods and compositions relating to ccr5 antagonist, ifn-.gamma. and il-13 induced inflammation
TW200610761A (en) * 2004-04-23 2006-04-01 Astrazeneca Ab Chemical compounds
AR050253A1 (es) 2004-06-24 2006-10-11 Smithkline Beecham Corp Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento
NZ553696A (en) 2004-09-13 2010-02-26 Ono Pharmaceutical Co Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient
TW200626142A (en) 2004-09-21 2006-08-01 Glaxo Group Ltd Chemical compounds
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
US7759365B2 (en) 2005-04-30 2010-07-20 Boehringer Ingelheim International Gmbh Piperidine-substituted indoles
WO2006129679A1 (ja) 2005-05-31 2006-12-07 Ono Pharmaceutical Co., Ltd. スピロピペリジン化合物およびその医薬用途
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
JP2009515833A (ja) * 2005-10-24 2009-04-16 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ３−ピペリジン−４−イル−インドールｏｒｌ−１受容体モジュレーター
PT1942108E (pt) 2005-10-28 2013-10-24 Ono Pharmaceutical Co Composto com um grupo básico e a sua utilização
ES2407115T3 (es) 2005-11-18 2013-06-11 Ono Pharmaceutical Co., Ltd. Compuesto que contiene un grupo básico y uso del mismo
AU2007225836A1 (en) 2006-03-10 2007-09-20 Ono Pharmaceutical Co., Ltd. Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
EP2042503B1 (en) 2006-05-16 2013-01-30 Ono Pharmaceutical Co., Ltd. Compound having acidic group which may be protected, and use thereof
TW200804383A (en) 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
WO2008016006A1 (en) 2006-07-31 2008-02-07 Ono Pharmaceutical Co., Ltd. Compound having cyclic group bound thereto through spiro binding and use thereof
JP5581055B2 (ja) * 2006-10-27 2014-08-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピペリジル−プロパン−チオールｃｃｒ３モジュレーター
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
CN102276581B (zh) * 2011-08-05 2013-06-12 上海师范大学 N-取代四氢吡啶连吲哚类化合物及其制备方法及应用
EP2741777B1 (en) 2011-08-12 2017-01-18 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for treatment of pulmonary hypertension
CN102898523B (zh) * 2012-10-19 2014-06-25 上海师范大学 N-取代四氢吡啶连吲哚-单克隆抗体cd14结合物及其制备方法和应用
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2193584B1 (es) * 1972-07-28 1975-08-08 Roussel Uclaf
FR2421899A1 (fr) * 1978-01-16 1979-11-02 Roussel Uclaf Nouveaux derives du tetrahydropyridinyl-indole et leurs sels, le procede de preparation et l'application a titre de medicaments de ces nouveaux produits
IE58370B1 (en) * 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
KR0131327B1 (en) * 1987-08-13 1998-04-17 Glaxo Group Ltd Indole derivatives
GB8719167D0 (en) * 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
DK158590D0 (da) * 1990-07-02 1990-07-02 Lundbeck & Co As H Indolderivater
AU654548B2 (en) * 1991-04-23 1994-11-10 Toray Industries, Inc. Tricyclic triazole derivative, production thereof, and use thereof
ZA954689B (en) * 1994-06-08 1996-01-29 Lundbeck & Co As H 4-Aryl-1-(indanmethyl dihydrobenzofuranmethyl or dihydrobenzothiophenemethyl) piperidines tetrahydropyridines or piperazines
US5521196A (en) * 1994-10-05 1996-05-28 Eli Lilly And Company 5-HT1F agonists for the treatment of migraine
US5521197A (en) 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
US5688927A (en) 1995-06-07 1997-11-18 Icos Corporation Macrophage derived chemokine
US5846982A (en) * 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake

Also Published As

Publication number Publication date
AR013669A1 (es) 2001-01-10
US6476028B1 (en) 2002-11-05
JP2001518505A (ja) 2001-10-16
CA2305805A1 (en) 1999-04-15
EP1037635A1 (en) 2000-09-27
AU9790198A (en) 1999-04-27
EP1037635A4 (en) 2002-11-13
WO1999017773A1 (en) 1999-04-15
ZA989083B (en) 1999-04-07

Similar Documents

Publication Publication Date Title
CO5011115A1 (es) Compuestos y metodos quimioquina
BR0108977A (pt) Compostos azacìclicos para uso no tratamento de doenças relaciondas com serotonina
AR035482A1 (es) Uso de un compuesto de cianoquinolina para la manufactura de un medicamento para tratar o inhibir polipos colonicos
AR012660A1 (es) Uso de compuestos de quinazolina para la manufactura de un medicamento util para el tratamiento de enfermedades poliquisticas del rinon.
AR039416A1 (es) Un metodo para prevenir y/o tratar el rechazo cronico en un organo o un tejido transplantado
MXPA02012763A (es) Combinaciones de inhibidores de dipeptidil peptidasa iv y otros agentes antidiabeticos para el tratamiento de diabetes mellitus.
ATE360630T1 (de) Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors
ATE266636T1 (de) Benzimidazolinone, benzoxazolinone, benzopiperazinone, indanone und deren derivate als faktor xa inhibitoren
KR960701051A (ko) 이미다조피리딘 및 이를 위장 질환의 치료에 사용하는 방법(imidazopyridines and their use in treating castrointestinal diseases)
BR0313743A (pt) Benzimidazol quinolinonas e usos destas
EA200100541A1 (ru) Фармацевтическая композиция с модифицированным высвобождением сенсибилизатора к инсулину и других антидиабетических агентов
NO2012015I1 (no) Dapoxetine i en hver form beskyttet av basis patent nr 330562
PA8542901A1 (es) Uso de (z)-2-ciano-3-hidroxi-but-2-acido enoico-(4-trifluorometilfenil)-amida para tratar la esclerosis multiple
DE69717148T2 (de) 3-pyridylenantiomere und ihre verwendung als analgetika
DE69928226D1 (de) Chemokin rezeptor antagonisten und verwndung
CO5200778A1 (es) Composicion farmaceutica que comprende una cantidad terapeuticamente efectiva de b enzimidazol, administrada para prevenir y tratar el cancer e inhibir la metastasis
TR200200263T2 (tr) Yeni seçiçi retinoid agonistleri
ES2133324T3 (es) Compuestos de dibenzoxazepina sustituidos, composiciones farmaceuticas y metodos de uso.
ES2180933T3 (es) Inhibidor de la serina-proteasa.
CO4960654A1 (es) Metodo para el tratamiento de enfermedades fisiologicas relacionadas con el uso o con las secuelas provocadas por el uso de la cocaina u otros estimulantes psicomotores
NO970340L (no) Organiske forbindelser
DK0986393T3 (da) Anvendelse af et nitroxid eller et prodrug heraf ved profylaktisk og terapeutisk behandling af cancer
PT1294732E (pt) Compostos de rutenio (ii) para utilizacao na terapia do cancro
NZ511559A (en) Use of staurosporine derivatives for treating ocular neovascular diseases
EE9800037A (et) Sulfaamhappe derivaatide, atsüülsulfoonamiidide või sulfonüülkarbamaatide kasutamine lipoproteiini tasemeid vähendava ravimi valmistamiseks